Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.56 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.56 |
| ▸ | CDK1 | P06493 | 3/20 | 0.56 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.56 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.56 |
| ▸ | GSK3A | P49840 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 2/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.56 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.56 |
| ▸ | EGFR | P00533 | 8/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.47 |
| ▸ | CSF1R | P07333 | 3/20 | 0.45 |
| ▸ | PRKCI | P41743 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20928367 | 0.80 | ADORA2A (0.56) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL16041244 | 0.80 | CDC7 (0.59) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL31240593 | 0.80 | CDC7 (0.59) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL1778024 | 0.80 | ADORA2A (0.56) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL1840887 | 0.78 | AURKA (0.44) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL25145758 | 0.78 | ADORA2A (0.54) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL4736127 | 0.77 | AURKA (0.60) | EGFRCSF1R | |
| SCHEMBL29955037 | 0.76 | ADORA2A (0.52) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL29957029 | 0.76 | ADORA2A (0.56) | ADORA2AADORA1CCNB2CDK1CCNB1 | |
| SCHEMBL26104732 | 0.76 | KDM5A (0.61) | ADORA2AADORA1CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016307-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016307-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016307-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| WO-2008049855-A2 | 7-AZAINDOLE DERIVATIVES AS C-MET KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016307-A1 | NOVEL COMPOUNDS | MET, HGF, HGFAC | ADORA2A 1919/4885ADORA1 2661/4885CCNB2 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.